For most of the past year, Treace Medical Concepts has asked investors to look past shrinking sales and focus on surgeon behavior. Case volumes are rising, new bunion systems are winning adopters, and management says the pricing drag from cheaper minimally invasive products should fade once it laps in the third quarter. The September-quarter report is where that argument stops being a forecast and starts being a test, because this is the period when stronger procedure counts are supposed to begin translating into healthier revenue trends.

The Street is not expecting a turnaround yet. Consensus calls for a loss of $0.25 per share, a touch better than the $0.26 loss a year ago, on revenue of roughly $47.7 million. That would be a 5% decline from $50.2 million in the prior-year quarter, slightly worse than the 4% drop Treace posted in the June quarter. That detail matters. If the average selling price headwind really is rolling off, analysts appear to be building in a cushion, which leaves room for upside if the improvement shows up on schedule. A decline that fails to narrow from the second quarter's pace, despite the easier mix comparison, would raise uncomfortable questions about whether softer elective demand is absorbing the benefit.

Guidance frames the bar. Management narrowed its full-year revenue outlook to $204 million to $212 million last quarter by lifting the low end, the first net raise after two reaffirmations, and it also trimmed the expected adjusted EBITDA loss to $3 million to $5 million. Consensus of about $206.8 million sits in the lower half of that range, which suggests analysts accept the company's floor but are reluctant to underwrite much of the back-half recovery, especially since growth is expected to return only in the seasonally strong fourth quarter. A third-quarter result near consensus keeps the range intact; a clear beat would make the midpoint look conservative, while a shortfall would put the newly raised floor in doubt.

The operating details will carry more weight than the headline numbers. Case volume growth accelerated to high single digits in the second quarter after holding at mid-single digits for three straight periods, and the share of the 3,300-plus Lapoplasty surgeon base using one of the three 2025 bunion systems climbed to around 40% from 35%. Sustaining or extending both trends would validate the idea that Treace is gaining share even in a sluggish procedure market. Investors should also look for full commercial traction on the SuperBite compression screw system and early signs of pull-through from the midfoot and hindfoot additions, plus confirmation that Cartoblaster and Lapoplasty Lightning remain on track for fourth-quarter launches. Those products underpin the company's pitch of a roughly $300 million expansion in addressable market. On the cost side, operating expenses fell 8% last quarter, and continued discipline matters because cash slipped to $45.6 million from $51.9 million in a single quarter.

Market sentiment is mildly positive but slightly cooler than before the last report, and the stock has slipped about 6% since then while the S&P 500 was essentially flat. Context softens that: shares rallied from below $2 to nearly $5 in the prior quarter, and at $4.83 the stock still trades well above its 200-day moving average of $3.21, sitting in the upper part of its post-earnings range of $3.78 to $5.20. In other words, much of the recovery story is already reflected in the price, and the recent pause looks more like digestion than rejection.

The central question is simple: does the third quarter show the revenue gap closing as the mix headwind laps? If volume growth holds in the high single digits, adoption keeps rising and the cash drain moderates, the improving narrative stays intact heading into a pivotal fourth quarter. If revenue declines fail to narrow, the market will likely conclude the turnaround is slipping further out.